Description
Medpace Holdings’ $3.2 Billion Backlog Hides a Growing Risk — Here’s Why!
Medpace Holdings, Inc. reported third-quarter 2026 results reflecting moderate revenue and profitability growth amid a strong, albeit cautiously viewed, business environment. Revenue increased 8.5% year-over-year to $716 million, contributing to a 16.9% rise in year-to-date revenue reaching $2.13 billion. EBITDA advanced 16% to $172.1 million for the quarter with margins expanding to 24%, up from 22.5% a year earlier, largely driven by lower reimbursable costs and favorable operational leverage. Net income grew 23.7% to $137.5 million, supported by higher interest income and a reduced effective tax rate, while diluted earnings per share rose to $4.84 from $3.86 in the prior year quarter. The company’s backlog increased 5.6% year-over-year to $3.2 billion, with net new business awards up 10.6% over the prior year quarter, setting an all-time high. Award growth over the last twelve months reached 23.9%, underpinning expectations for continued revenue conversion from backlog estimated at approximately $1.



